Abstract

The objective of this contract is to provide a coordinating center for a multi-center phase II-B randomized controlled study of tissue plasminogen activator for acute ischemic stroke. The work to be performed by the Contractor includes coordination of the clinical trial, maintenance and coordination of data collection, data analysis, quality control, and writing of final collaborative report(s).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research and Development Contracts (N01)
Project #
N01NS002382-000
Application #
2321229
Study Section
Project Start
1990-06-11
Project End
1993-06-10
Budget Start
1990-06-11
Budget End
1991-06-10
Support Year
Fiscal Year
1990
Total Cost
Indirect Cost

  Institution

Name
Henry Ford Health System
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202

  Publications

Lees, Kennedy R; Bluhmki, Erich; von Kummer, Rüdiger et al. (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375:1695-703
Nichols, Christopher; Khoury, Jane; Brott, Thomas et al. (2008) Intravenous recombinant tissue plasminogen activator improves arterial recanalization rates and reduces infarct volumes in patients with hyperdense artery sign on baseline computed tomography. J Stroke Cerebrovasc Dis 17:64-8
Jauch, Edward C; Lindsell, Christopher; Broderick, Joseph et al. (2006) Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 37:2508-13
Tanne, David; Macko, Richard F; Lin, Yan et al. (2006) Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 37:1798-804
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group (2005) Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 46:243-52
Kwiatkowski, Thomas; Libman, Richard; Tilley, Barbara C et al. (2005) The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. Ann Emerg Med 45:377-84
Lu, Mei; Lyden, Patrick D; Brott, Thomas G et al. (2005) Beyond subgroup analysis: improving the clinical interpretation of treatment effects in stroke research. J Neurosci Methods 143:209-16
Hacke, Werner; Donnan, Geoffrey; Fieschi, Cesare et al. (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363:768-74
Tanne, D; Levine, S R; Brey, R L et al. (2003) Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial. Neurology 61:1158-9
Bruno, A; Levine, S R; Frankel, M R et al. (2002) Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology 59:669-74

Showing the most recent 10 out of 32 publications